About Mallinckrodt PLC (NYSE:MNK)
Mallinckrodt public limited company develops, manufactures, markets and distributes branded and generic specialty pharmaceutical products and therapies. The Company focuses on various therapeutic areas, such as autoimmune and rare disease specialty areas, including neurology, rheumatology, nephrology, ophthalmology and pulmonology; immunotherapy and neonatal critical care respiratory therapies; analgesics and hemostasis products, and central nervous system drugs. Its segments include Specialty Brands and Specialty Generics. The Specialty Brands segment produces and markets branded pharmaceutical products and therapies. The Specialty Generics segment produces and markets specialty generic pharmaceuticals and active pharmaceutical ingredient (API) consisting of biologics, medicinal opioids, synthetic controlled substances, acetaminophen and other active ingredients. Its product portfolio includes Acthar, Inomax, Ofirmev, Therakos immunotherapy, Hemostasis products and StrataGraft.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Specialty & Advanced Pharmaceuticals
- Sub-Industry: N/A
- Symbol: NYSE:MNK
- CUSIP: N/A
- Web: www.mallinckrodt.com
Capitalization:- Market Cap: $3.21485 billion
- Outstanding Shares: 97,178,000
Average Prices:- 50 Day Moving Avg: $36.24
- 200 Day Moving Avg: $41.42
- 52 Week Range: $31.78 - $68.43
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: 4.00
- P/E Growth: 0.84
Sales & Book Value:- Annual Revenue: $3.27 billion
- Price / Sales: 0.96
- Book Value: $52.46 per share
- Price / Book: 0.61
Profitability:- EBITDA: $666.6 million
- Net Margins: 12.64%
- Return on Equity: 15.28%
- Return on Assets: 5.20%
Debt:- Debt-to-Equity Ratio: 1.05%
- Current Ratio: 1.06%
- Quick Ratio: 0.81%
Misc:- Average Volume: 2.51 million shs.
- Beta: 1.51
- Short Ratio: 7.62
Frequently Asked Questions for Mallinckrodt PLC (NYSE:MNK)
What is Mallinckrodt PLC's stock symbol?
Mallinckrodt PLC trades on the New York Stock Exchange (NYSE) under the ticker symbol "MNK."
How will Mallinckrodt PLC's stock buyback program work?
Mallinckrodt PLC announced that its board has initiated a stock repurchase program on Sunday, April 9th 2017, which authorizes the company to buyback $1,000,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization authorizes the company to buy up to 18.5% of its stock through open market purchases. Stock buyback programs are typically a sign that the company's board believes its stock is undervalued.
How were Mallinckrodt PLC's earnings last quarter?
Mallinckrodt PLC (NYSE:MNK) issued its quarterly earnings results on Tuesday, August, 8th. The company reported $1.85 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.73 by $0.12. The company earned $824.50 million during the quarter, compared to the consensus estimate of $829.56 million. Mallinckrodt PLC had a return on equity of 15.28% and a net margin of 12.64%. Mallinckrodt PLC's quarterly revenue was down 4.9% compared to the same quarter last year. During the same period last year, the firm posted $2.03 EPS. View Mallinckrodt PLC's Earnings History.
When will Mallinckrodt PLC make its next earnings announcement?
What guidance has Mallinckrodt PLC issued on next quarter's earnings?
Mallinckrodt PLC issued an update on its FY17 earnings guidance on Tuesday, August, 8th. The company provided EPS guidance of $7.40-8.00 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $7.53.
Where is Mallinckrodt PLC's stock going? Where will Mallinckrodt PLC's stock price be in 2017?
17 analysts have issued 12 month price targets for Mallinckrodt PLC's shares. Their forecasts range from $40.00 to $98.00. On average, they anticipate Mallinckrodt PLC's share price to reach $59.97 in the next twelve months. View Analyst Ratings for Mallinckrodt PLC.
What are analysts saying about Mallinckrodt PLC stock?
Here are some recent quotes from research analysts about Mallinckrodt PLC stock:
- 1. According to Zacks Investment Research, "Mallinckrodt is currently focused on reshaping its product portfolio through strategic acquisitions and non-core asset divestitures to transform the portfolio and become a high-performing specialty pharmaceutical company. The company sold its Nuclear Imaging business and Intrathecal Therapy business to focus on its key areas. While Acthar sales continue to be strong on the back of increased formulary positions and access for appropriate patients in both the commercial and public environments, sales of Therakos is expected to decline. The generic segment continues to face weakness as various product categories are witnessing stiff competition, which is hurting both their volumes and prices. The company expects double-digit declines in revenues from this segment. Shares of the company have underperformed the industry so far in 2017." (10/17/2017)
- 2. Mizuho analysts commented, "We reiterate our Buy rating and $73 PT and push back against short-seller inaccuracies and Acthar pricing concerns." (5/31/2017)
- 3. Guggenheim analysts commented, "Although any potential competition for MNK's largest single drug, Acthar, is a concern, we think that it will take at least several years for Marathon to even establish proof of concept for its product, which means there is no near-to-mid-term threat here. We forecast Acthar sales of $1.2B in '16 and total MNK sales of $3.3B. We believe that MNK's execution of its stated business objectives is underappreciated and would note that the company has a demonstrated record of success, supported by consistent earnings beats over the last five quarters. We continue to believe strong execution of MNK's growth initiatives will drive P/E multiple expansion (from 6x to at least 10x, average pharma trough multiple) and put MNK shares back on a path to $70+." (1/19/2017)
Who are some of Mallinckrodt PLC's key competitors?
Some companies that are related to Mallinckrodt PLC include ConvaTec Group PLC (CTEC), Advanced Accelerator Applications S.A. (AAAP), Indivior PLC (INDV), Supernus Pharmaceuticals (SUPN), Aimmune Therapeutics (AIMT), Repligen Corporation (RGEN), TherapeuticsMD (TXMD), TherapeuticsMD (TXMD), Eagle Pharmaceuticals (EGRX), Assembly Biosciences (ASMB), Rockwell Medical (RMTI), NOVAN INC (NOVN), CorMedix (CRMD), Check-Cap (CHEK), DARA Biosciences (DARA), Macrocure Ltd (MCUR) and Salix Pharmaceuticals (SLXP).
Who are Mallinckrodt PLC's key executives?
Mallinckrodt PLC's management team includes the folowing people:
- Melvin D. Booth Ph.D., CPA, Independent Chairman of the Board
- Mark C. Trudeau, President, Chief Executive Officer, Director
- Matthew K. Harbaugh, Chief Financial Officer, Executive Vice President
- Ian J. Watkins, Chief Human Resource Officer
- Ronald K. Lloyd, Executive Vice President and President - Hospital Therapies
- Gary M. Phillips M.D., Executive Vice President and Chief Strategy Officer
- Steven Romano, Executive Vice President and Chief Scientific Officer
- Frank Scholz, Executive Vice President of Global Operations and President - Specialty Generics
- Hugh O'Neill, Senior Vice President and President - Autoimmune and Rare Diseases
- Raymond J. Furey, Chief Compliance Officer
How do I buy Mallinckrodt PLC stock?
Shares of Mallinckrodt PLC can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Mallinckrodt PLC's stock price today?
One share of Mallinckrodt PLC stock can currently be purchased for approximately $32.16.
MarketBeat Community Rating for Mallinckrodt PLC (NYSE MNK)MarketBeat's community ratings are surveys of what our community members think about Mallinckrodt PLC and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Mallinckrodt PLC (NYSE:MNK) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 4 Hold Ratings, 13 Buy Ratings |
| Consensus Rating: | Buy (Score: 2.76) |
| Consensus Price Target: | $59.97 (86.48% upside) |
Consensus Price Target History for Mallinckrodt PLC (NYSE:MNK)
Analysts' Ratings History for Mallinckrodt PLC (NYSE:MNK)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 10/15/2017 | Mizuho | Reiterated Rating | Hold | $40.00 | N/A |  |
| 10/6/2017 | Stifel Nicolaus | Reiterated Rating | Buy | | N/A | |
| 10/6/2017 | Jefferies Group LLC | Reiterated Rating | Buy | $60.00 | N/A | |
| 10/5/2017 | Piper Jaffray Companies | Reiterated Rating | Buy | $67.00 | N/A | |
| 10/4/2017 | Canaccord Genuity | Downgrade | Buy -> Hold | $77.00 -> $40.00 | N/A | |
| 10/2/2017 | Cantor Fitzgerald | Set Price Target | Buy | $52.00 | Medium | |
| 9/28/2017 | Goldman Sachs Group, Inc. (The) | Initiated Coverage | Buy -> Buy | $55.00 | Medium | |
| 9/19/2017 | Oppenheimer Holdings, Inc. | Lower Price Target | | $70.00 -> $48.00 | Low | |
| 9/14/2017 | Deutsche Bank AG | Reiterated Rating | Buy | $56.00 -> $45.00 | Low | |
| 9/14/2017 | Citigroup Inc. | Lower Price Target | Reduce -> Buy | $45.00 | Low | |
| 9/6/2017 | Morgan Stanley | Downgrade | Overweight -> Equal Weight | $65.00 -> $40.00 | Low | |
| 8/9/2017 | BMO Capital Markets | Reiterated Rating | Outperform | $69.00 -> $65.00 | Low | |
| 8/9/2017 | Raymond James Financial, Inc. | Lower Price Target | Outperform | $65.00 -> $58.00 | Low | |
| 6/21/2017 | Wells Fargo & Company | Reiterated Rating | Outperform | $83.50 | High | |
| 4/1/2017 | Guggenheim | Set Price Target | Buy | $98.00 | Low | |
| 3/20/2017 | Leerink Swann | Reiterated Rating | Outperform | | Low | |
| 1/25/2017 | J P Morgan Chase & Co | Set Price Target | Hold | $78.00 | N/A | |
| 8/25/2016 | Barclays PLC | Reiterated Rating | Overweight | $88.00 | N/A | |
| 3/16/2016 | Northland Securities | Reiterated Rating | Buy | $95.00 | N/A | |
| 2/2/2016 | Nomura | Reiterated Rating | Neutral | $100.00 | N/A | |
(Data available from 10/19/2015 forward)
Earnings History for Mallinckrodt PLC (NYSE:MNK)Earnings History by Quarter for Mallinckrodt PLC (NYSE MNK)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 11/7/2017 | | $1.82 | | | | | N/A | |
| 8/8/2017 | Q2 2017 | $1.73 | $1.85 | $829.56 million | $824.50 million | View | Listen | |
| 5/8/2017 | Q1 2017 | $1.63 | $1.68 | $781.23 million | $810.90 million | View | Listen | |
| 2/7/2017 | Q117 | $1.82 | $1.91 | $827.12 million | $829.90 million | View | Listen | |
| 11/29/2016 | Q416 | $1.98 | $2.04 | $880.10 million | $887.20 million | View | Listen | |
| 8/2/2016 | Q316 | $2.01 | $2.20 | $920.35 million | $970.60 million | View | Listen | |
| 5/3/2016 | Q216 | $1.72 | $2.01 | $878.70 million | $918.00 million | View | Listen | |
| 2/2/2016 | Q116 | $1.78 | $2.09 | $888.33 million | $915.00 million | View | Listen | |
| 11/23/2015 | Q415 | $1.77 | $1.84 | $869.41 million | $882.40 million | View | Listen | |
| 8/4/2015 | Q315 | $1.82 | $2.05 | $983.81 million | $965.10 million | View | Listen | |
| 5/5/2015 | Q215 | $1.48 | $1.72 | $860.89 million | $909.90 million | View | Listen | |
| 2/3/2015 | Q115 | $1.57 | $1.84 | $880.12 million | $866.00 million | View | Listen | |
| 11/19/2014 | Q414 | $1.41 | $1.68 | $759.04 million | $789.00 million | View | Listen | |
| 8/7/2014 | Q314 | $0.86 | $1.20 | $278.80 million | $653.10 million | View | Listen | |
| 5/8/2014 | Q214 | $0.79 | $0.95 | $566.50 million | $557.80 million | View | Listen | |
| 2/6/2014 | Q1 | $0.66 | $0.88 | $539.24 million | $540.20 million | View | Listen | |
| 11/7/2013 | | $0.85 | $1.02 | $572.57 million | $552.20 million | View | Listen | |
| 8/9/2013 | Q3 2013 | $0.78 | $0.49 | $557.22 million | $570.00 million | View | Listen | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Mallinckrodt PLC (NYSE:MNK)2017 EPS Consensus Estimate: $7.48
2018 EPS Consensus Estimate: $8.27
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 3 | $1.54 | $1.84 | $1.71 |
| Q2 2017 | 3 | $1.70 | $1.95 | $1.80 |
| Q3 2017 | 3 | $1.81 | $1.89 | $1.86 |
| Q4 2017 | 3 | $1.95 | $2.35 | $2.11 |
| Q1 2018 | 3 | $1.61 | $1.82 | $1.70 |
| Q2 2018 | 2 | $1.91 | $2.15 | $2.03 |
| Q3 2018 | 2 | $2.03 | $2.10 | $2.07 |
| Q4 2018 | 2 | $2.48 | $2.48 | $2.48 |
(Data provided by Zacks Investment Research)
Dividend History for Mallinckrodt PLC (NYSE:MNK)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Mallinckrodt PLC (NYSE:MNK)Insider Ownership Percentage: 0.77%
Institutional Ownership Percentage: 97.36%
Insider Trades by Quarter for Mallinckrodt PLC (NYSE:MNK)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 8/30/2017 | Meredith B. Fischer | Insider | Buy | 1,280 | $39.63 | $50,726.40 | |
| 6/9/2017 | Steven J. Romano | VP | Buy | 1,000 | $39.88 | $39,880.00 | |
| 6/8/2017 | Hugh M. O'neill | VP | Buy | 1,000 | $40.24 | $40,240.00 | |
| 6/5/2017 | Coleman N Lannum III | VP | Buy | 500 | $39.33 | $19,665.00 | |
| 6/2/2017 | Coleman N Lannum III | VP | Buy | 1,350 | $42.89 | $57,901.50 | |
| 5/12/2017 | Coleman N. Lannum III | VP | Buy | 1,968 | $46.20 | $90,921.60 | |
| 3/10/2017 | Matthew K. Harbaugh | CFO | Buy | 600 | $49.19 | $29,514.00 | |
| 3/7/2017 | Michael-Bryant Hicks | General Counsel | Buy | 290 | $50.35 | $14,601.50 | |
| 2/23/2017 | Meredith B. Fischer | Insider | Buy | 2,000 | $54.34 | $108,680.00 | |
| 2/14/2017 | Mark Trudeau | Insider | Buy | 1,000 | $50.47 | $50,470.00 | |
| 2/10/2017 | Steven J. Romano | VP | Buy | 1,000 | $49.68 | $49,680.00 | |
| 5/10/2016 | Hugh M O'neill | VP | Buy | 1,653 | $60.99 | $100,816.47 | |
| 5/10/2016 | Matthew K Harbaugh | CFO | Buy | 500 | $59.37 | $29,685.00 | |
| 5/6/2016 | Mark Trudeau | CEO | Buy | 1,000 | $56.02 | $56,020.00 | |
| 5/6/2016 | Steven J Romano | VP | Buy | 900 | $56.00 | $50,400.00 | |
| 3/4/2016 | Coleman N Lannum III | VP | Buy | 2,600 | $62.63 | $162,838.00 | |
| 2/26/2016 | Meredith B Fischer | VP | Buy | 1,400 | $69.80 | $97,720.00 | |
| 2/12/2016 | Coleman N Lannum III | VP | Buy | 600 | $59.66 | $35,796.00 | |
| 2/10/2016 | Coleman N Lannum III | VP | Buy | 1,300 | $62.58 | $81,354.00 | |
| 2/9/2016 | Matthew K. Harbaugh | CFO | Buy | 1,300 | $63.00 | $81,900.00 | |
| 2/8/2016 | Coleman N. Lannum III | VP | Buy | 800 | $66.37 | $53,096.00 | |
| 12/22/2015 | Coleman N Lannum III | SVP | Buy | 500 | $72.50 | $36,250.00 | |
| 12/11/2015 | Terrance L Carlson | General Counsel | Buy | 1,000 | $69.10 | $69,100.00 | |
| 12/2/2015 | Gary M. Phillips | VP | Buy | 1,000 | $72.17 | $72,170.00 | |
| 11/30/2015 | Mark Trudeau | CEO | Buy | 1,350 | $65.89 | $88,951.50 | |
| 11/27/2015 | Coleman N Lannum III | SVP | Buy | 1,200 | $66.86 | $80,232.00 | |
| 11/27/2015 | Meredith B Fischer | VP | Buy | 2,200 | $66.93 | $147,246.00 | |
| 11/27/2015 | Terrance L Carlson | General Counsel | Buy | 1,000 | $66.54 | $66,540.00 | |
| 8/25/2015 | Hugh M O'neill | SVP | Buy | 1,197 | $83.52 | $99,973.44 | |
| 8/25/2015 | Mark Trudeau | CEO | Buy | 1,000 | $83.08 | $83,080.00 | |
| 8/21/2015 | Coleman N Lannum III | SVP | Buy | 2,375 | $88.52 | $210,235.00 | |
| 8/21/2015 | Mark Trudeau | CEO | Buy | 2,000 | $88.45 | $176,900.00 | |
| 6/4/2015 | Coleman N Lannum III | VP | Buy | 1,300 | $126.41 | $164,333.00 | |
| 6/2/2015 | Matthew K Harbaugh | CFO | Sell | 22,106 | $128.64 | $2,843,715.84 | |
| 5/18/2015 | Mario D Saltarelli | VP | Sell | 4,580 | $127.44 | $583,675.20 | |
| 5/13/2015 | Don M Bailey | Director | Sell | 51,417 | $122.45 | $6,296,011.65 | |
| 5/11/2015 | Sandra L Hatten | VP | Sell | 2,024 | $122.29 | $247,514.96 | |
| 4/13/2015 | Don M Bailey | Director | Sell | 40,000 | $127.61 | $5,104,400.00 | |
| 3/13/2015 | Don M Bailey | Director | Sell | 40,000 | $123.40 | $4,936,000.00 | |
| 2/13/2015 | Don M Bailey | Director | Sell | 33,891 | $114.63 | $3,884,925.33 | |
| 2/2/2015 | Mark Trudeau | CEO | Sell | 11,925 | $105.94 | $1,263,334.50 | |
| 1/9/2015 | Mark Trudeau | CEO | Sell | 15,720 | $102.00 | $1,603,440.00 | |
| 12/22/2014 | Peter G Edwards | VP | Sell | 1,265 | $99.69 | $126,107.85 | |
| 12/18/2014 | Mark Trudeau | CEO | Sell | 13,831 | $93.59 | $1,294,443.29 | |
| 9/10/2014 | Raymond J Furey | VP | Sell | 5,441 | $85.90 | $467,381.90 | |
| 9/8/2014 | Don M Bailey | Director | Sell | 221,177 | $85.23 | $18,850,915.71 | |
| 9/5/2014 | Raymond J Furey | VP | Sell | 15,000 | $85.47 | $1,282,050.00 | |
| 9/5/2014 | Virgil D Thompson | Director | Sell | 25,000 | $83.76 | $2,094,000.00 | |
| 9/2/2014 | Raymond J Furey | VP | Sell | 10,303 | $81.61 | $840,827.83 | |
| 8/29/2014 | Raymond J Furey | VP | Sell | 4,840 | $80.90 | $391,556.00 | |
| 8/19/2014 | Joseph A Zaccagnino | Director | Buy | 3,000 | $71.06 | $213,180.00 | |
| 8/13/2014 | Paulson & Co Inc | Major Shareholder | Buy | 132,100 | $69.80 | $9,220,580.00 | |
| 8/12/2014 | J Martin Carroll | Director | Buy | 2,000 | $69.24 | $138,480.00 | |
| 8/12/2014 | Paulson & Co Inc | Major Shareholder | Buy | 467,900 | $68.78 | $32,182,162.00 | |
| 8/11/2014 | Paulson & Co Inc | Major Shareholder | Buy | 207,900 | $69.70 | $14,490,630.00 | |
| 8/7/2014 | Paulson & Co Inc | Major Shareholder | Buy | 700,200 | $70.15 | $49,119,030.00 | |
| 8/1/2014 | Paulson & Co Inc | Major Shareholder | Buy | 275,000 | $69.60 | $19,140,000.00 | |
| 6/11/2014 | Melvin D Booth | Director | Buy | 4,000 | $76.05 | $304,200.00 | |
| 5/9/2014 | Paulson & Co Inc | major shareholder | Buy | 786,207 | $73.63 | $57,888,421.41 | |
| 2/3/2014 | Mark Trudeau | CEO | Sell | 14,890 | $56.12 | $835,626.80 | |
(Data available from 1/1/2013 forward)
Headline Trends for Mallinckrodt PLC (NYSE:MNK)
Latest Headlines for Mallinckrodt PLC (NYSE:MNK)
| Source: |
|
| Date | Headline |
|---|
 | Mallinckrodt PLC (MNK) Downgraded by Zacks Investment Research
www.americanbankingnews.com - October 17 at 2:52 PM |
 | The Final Straw For Mallinckrodt? - Seeking Alpha
seekingalpha.com - October 16 at 11:15 PM |
 | Mallinckrodt Opens Specialty Brands Office In New Jersey, Announces $100,000 Donation To Princeton University Program For High Achieving, Low-Income High School Students
finance.yahoo.com - October 16 at 11:15 PM |
| Reviewing Mallinckrodt PLC (MNK) & Its Competitors
www.americanbankingnews.com - October 16 at 12:32 PM |
| Mallinckrodt PLC (MNK) & Its Rivals Head to Head Analysis
www.americanbankingnews.com - October 16 at 9:04 AM |
| Mallinckrodt PLC's (MNK) "Hold" Rating Reiterated at Mizuho
www.americanbankingnews.com - October 15 at 7:56 AM |
| Mallinckrodt PLC (MNK) versus The Competition Head to Head Comparison
www.americanbankingnews.com - October 14 at 12:46 AM |
| Mallinckrodt PLC (MNK) Expected to Earn FY2018 Earnings of $8.34 Per Share
www.americanbankingnews.com - October 12 at 1:54 PM |
| Mallinckrodt PLC (MNK) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - October 12 at 6:12 AM |
| DARA Biosciences (DARA) vs. Mallinckrodt PLC (MNK) Head to Head Analysis
www.americanbankingnews.com - October 11 at 4:30 PM |
| Analysts Issue Forecasts for Mallinckrodt PLC's Q3 2017 Earnings (MNK)
www.americanbankingnews.com - October 11 at 6:32 AM |
 | Mallinckrodt to Begin Sarcoidosis Study on Acthar Gel - Nasdaq.com - Nasdaq
www.nasdaq.com - October 10 at 11:52 PM |
 | Mallinckrodt plc to Report Earnings Results for Third Quarter of Fiscal 2017 - PR Newswire (press release)
www.prnewswire.com - October 10 at 11:52 PM |
| Mallinckrodt plc to Report Earnings Results for Third Quarter of Fiscal 2017
finance.yahoo.com - October 10 at 11:52 PM |
| Mallinckrodt Will Conduct Phase 4 Trial of H.P. Acthar® Gel (Repository Corticotropin Injection) for Symptomatic Sarcoidosis
finance.yahoo.com - October 9 at 8:22 PM |
 | Mallinckrodt (MNK) Plans Phase 4 Trial of HP Acthar Gel for Symptomatic Sarcoidosis - StreetInsider.com
www.streetinsider.com - October 9 at 3:20 PM |
| Mallinckrodt PLC (MNK) and TherapeuticsMD (TXMD) Critical Contrast
www.americanbankingnews.com - October 8 at 6:30 AM |
| Mallinckrodt PLC (MNK) Earns Buy Rating from Stifel Nicolaus
www.americanbankingnews.com - October 6 at 4:52 PM |
| Mallinckrodt plc Discusses Pipeline Transformation, Company Outlook at Investor Briefing - PR Newswire (press release)
www.prnewswire.com - October 6 at 10:41 AM |
| Mallinckrodt PLC (MNK) Earns Buy Rating from Jefferies Group LLC
www.americanbankingnews.com - October 6 at 9:36 AM |
| Mallinckrodt PLC (MNK) Given a $70.00 Price Target at UBS AG
www.americanbankingnews.com - October 6 at 9:12 AM |
| Mallinckrodt PLC (MNK) Rating Lowered to Hold at Canaccord Genuity
www.americanbankingnews.com - October 4 at 9:14 PM |
| Mallinckrodt, NeuroproteXeon Team Up for Inhalation Therapy - Nasdaq
www.nasdaq.com - October 4 at 8:33 AM |
| Mallinckrodt Details Development Pipeline Highlights - Quick Facts - Nasdaq
www.nasdaq.com - October 4 at 8:33 AM |
| Mallinckrodt PLC (MNK) PT Set at $52.00 by Cantor Fitzgerald
www.americanbankingnews.com - October 2 at 4:30 PM |
| Mallinckrodt (MNK) Announces Agreement to License Inhaled Xenon Gas Therapy Development Product - StreetInsider.com
www.streetinsider.com - October 2 at 11:45 AM |
| Mallinckrodt Licenses Inhaled Xenon Gas Therapy Development Product
finance.yahoo.com - October 2 at 11:45 AM |
| Mallinckrodt PLC (MNK) Now Covered by Analysts at Goldman Sachs Group, Inc. (The)
www.americanbankingnews.com - September 28 at 6:20 PM |
| ETFs with exposure to Mallinckrodt Plc : September 25, 2017
finance.yahoo.com - September 25 at 7:28 PM |
| Mallinckrodt Completes Acquisition of InfaCare Pharmaceutical Corporation and Stannsoporfin, its Proprietary Therapy in Late-Stage Development for Newborns at Risk for Severe Jaundice
finance.yahoo.com - September 25 at 7:28 PM |
| Mallinckrodt Advocates for Comprehensive, Multi-Prong Action Plan to Fight Opioid Abuse and Misuse in the United States
finance.yahoo.com - September 23 at 8:17 AM |
| Oppenheimer Holdings Brokers Decrease Earnings Estimates for Mallinckrodt PLC (MNK)
www.americanbankingnews.com - September 21 at 1:44 PM |
| Interesting MNK Put And Call Options For November 17th - Nasdaq
www.nasdaq.com - September 20 at 6:23 AM |
| Mallinckrodt Announces Election Of David Norton To Its Board Of Directors
finance.yahoo.com - September 20 at 6:23 AM |
| Mallinckrodt PLC (MNK) Price Target Lowered to $48.00 at Oppenheimer Holdings, Inc.
www.americanbankingnews.com - September 19 at 3:52 PM |
| Breakfast Technical Briefing on Generic Drugs Stocks -- Mallinckrodt, Horizon ...
www.prnewswire.com - September 18 at 11:02 PM |
 | Breakfast Technical Briefing on Generic Drugs Stocks -- Mallinckrodt, Horizon Pharma, Mylan, and Neurocrine Biosciences
www.bizjournals.com - September 18 at 11:02 PM |
| Mallinckrodt PLC (MNK) and Its Competitors Head to Head Contrast
www.americanbankingnews.com - September 18 at 4:28 AM |
| Mallinckrodt PLC (MNK) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - September 17 at 6:38 AM |
| Piper Jaffray Companies Reaffirms Buy Rating for Mallinckrodt PLC (MNK)
www.americanbankingnews.com - September 15 at 5:32 PM |
| Mallinckrodt (MNK): Cutting PT After Negative Ruling - Deutsche Bank - StreetInsider.com
www.streetinsider.com - September 14 at 9:08 PM |
| ETFs with exposure to Mallinckrodt Plc : September 14, 2017
finance.yahoo.com - September 14 at 9:08 PM |
| Mallinckrodt PLC (MNK) Given Buy Rating at Deutsche Bank AG
www.americanbankingnews.com - September 14 at 3:32 PM |
| Mallinckrodt PLC (MNK) PT Lowered to $45.00 at Citigroup Inc.
www.americanbankingnews.com - September 14 at 9:34 AM |
| Mizuho Securities Downgrades Mallinckrodt plc (MNK) to Neutral, Negatively Revises EPS Estimates
www.streetinsider.com - September 14 at 7:51 AM |
| Mallinckrodt Plc :MNK-US: Earnings Analysis: Q3, 2017 By the Numbers : September 13, 2017
finance.yahoo.com - September 14 at 7:51 AM |
| Mallinckrodt PLC (MNK) Downgraded by Mizuho
www.americanbankingnews.com - September 13 at 8:05 AM |
| The most respected medical journal in the US just eviscerated a drug that's cost taxpayers over $1 billion
finance.yahoo.com - September 13 at 6:38 AM |
| Mallinckrodt PLC (MNK) Downgraded by Morgan Stanley
www.americanbankingnews.com - September 10 at 7:34 PM |
| Mallinckrodt PLC's (MNK) Buy Rating Reaffirmed at Stifel Nicolaus
www.americanbankingnews.com - September 10 at 7:02 PM |
Mallinckrodt PLC (MNK) Chart for Thursday, October, 19, 2017
